Nuohe Nordic falls nearly 2%, Lilly claims that Zepbound's weight loss effect is far better than Wegovy.

Nuo and Nord fell nearly 2%, closing at $64.5. On the news front, Eli Lilly announced that its weight loss drug Zepbound outperformed Nuo and Nord's Wegovy in a comparative trial with five weight loss goals.